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Background/introduction
NANOPORATION project sets out to explore specific
solutions to overcome the current challenges of targeted
drug delivery (TDD) to tumours using magnetic reso-
nance imaging guided focused ultrasound (MRgFUS) to
cavitate microbubbles (MBs) for increasing cell perme-
ability and to open ‘drug nano-capsules’ for releasing pro-
ven active anticancer drugs directly to the tumour site
with reduction of drug dosage needed for the desired
therapeutic effect.
Methods
A novel gamma-Cyclodextrin (gamma-CD) based carrier
for encapsulation of doxorubicin (DOX) was synthesized
and fully characterized. The encapsulation efficiency was
assessed by chemical analysis, in vitro and in vivo. A
high-throughput in vitro micro-scale FUS device (soni-
cator) was designed and applied to cells exposure to car-
rier-DOX inclusion, in combination with SonoVue®
MBs to investigate TDD in monolayer cellular level. Ex
vivo and in vivo trials were carried out by clinical ExA-
blate MRgFUS system (InSightec, Israel) to establish a
safe and efficient clinical TDD protocol on small
rodents.
Results and conclusions
The desired gamma-CD based carrier greatly reduced
DOX’s toxicity in vitro: up to 95% toxicity reduction in
KB human enpidermal carcinoma; up to 92% toxicity
reduction in HCT116 colorectal carcinomar. Cellular
DOX uptake was reduced 73% in muscle, 69% in kidney,
66% in liver, 65% in heart, 62% in brain, 53% in lungs as
25% in plasma in vivo. The carrier-DOX inclusion is
highly stable under physiological temperature and pH as
well as under a wide range of acidic conditions (pH
1.0~7.0); the encapsulated DOX is slowly released under
hyperthermic conditions (up to 50°C). In the presence
of MBs (0.1%, 1%, 2.5% and 5%) application of FUS with
low mechanical indexes (0.24, 0.31 and 0.53), under
which no thermal effect was observed, enhanced up to
3.89-fold of cellular drug uptake for encapsulated DOX
in vitro. Optimal setup of MR parameters: TR/TE =
3180/96.3msec; bandwidth: 10.4 kHz; Field of View =
20 × 20cm; matrix: 384 × 384, NEX: 2; slice thickness:
2.0mm/1.0sp; number of slices: 8; frequency direction:
SI and the spatial resolution: 0.52mm; FUS parameters:
4W, 10sec continued sonication and 45sec pulsed soni-
cation with 2.5sec OFF and 0.5sec ON; temperature
increase of 7-10 °C; as well as treatment time frame of
35min were identified ex vivo and in vivo, which allowed
application of MRgFUS treatments to live mice bearing
tumors under anesthesia with full recovery.
Unfortunately, the lack of detectable DOX signal was
obtained from the very first pre-clinical trial. However,
the study demonstrated the possibility of translation of
the constructed gamma-CD derivative to potential clini-
cal use as a delivery vehicle of DOX for combined ther-
mal and mechanical mechanism by clinically applicable
MRgFUS, -triggered TDD for cancer therapy.
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Figure 1 AFM cell surface morphology comparison of KB cells before (A) and after (B) f=0.4868MHz sonication with 2.5% MBs
Figure 2 Animal positioning on ExAblate 2000 table inside rodent chamber (A); mouse was protected by gloves filled with water (B); on top of
coupling gel-pad with a small cut-out (C)
Figure 3 MRgFUS system: ExAblate 2000 (A); ExAblate 2100 with MR (B); a MR image of a sheep liver on top of ExAblate 2000 FUS transducer
(C)
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Figure 4 Example of Thermal Monitoring during sonication: Coronal MR image showing planned sonication location (A); temperature graph
during sonication (B); the anatomical image acquired during sonication (C)
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